Seminars in Oncology
Volume 30, Issue 2 , Pages 156-160, April 2003

Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias☆☆

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and the Department of Medicine, Harvard Medical School, Boston, MA.

Abstract 

The proteomic analysis of tumor cells emerges as a key complement to gene expression profiling, primarily because regulation of protein expression (at the translational and post-translational levels) can buffer the magnitude of changes occurring at the gene transcription level, in order to fine tune cellular functions. Herein we describe the concept of proteomic analysis of the signaling state of tumor cells, as well as its application in the study of signaling pathways in plasma cell dyscrasias, such as Waldenstrom's macroglobulinemia (WM) and multiple myeloma (MM). Comparative studies of WM versus MM cells at baseline and in the setting of drug treatment reveals proteomic profiles of the signaling state with significant overlap (that could reflect a putative B-cell lineage-related proteomic signature), but also distinct differences, possibly associated with differential features in the biologic behavior and drug sensitivity of these diseases. These proteomic studies pave the way for a more comprehensive insight into the molecular basis of WM versus other B-cell malignancies. Semin Oncol 30:156-60. © 2003 Elsevier Inc. All rights reserved.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by the International Waldenstrom's Macroglobulinemia Foundation (C.S.M), Multiple Myeloma Research Foundation (C.S.M and N.M.), Lauri Strauss Leukemia Foundation (C.S.M), and by a Doris Duke Distinguished Clinical Scientist Award (K.C.A).

☆☆ Address reprint requests to Kenneth C. Anderson, MD, Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney St, Mayer Building, Room M555, Boston, MA 02115.

 0093-7754/03/3002-3031$30.00/0

PII: S0093-7754(03)70068-2

doi:10.1053/sonc.2003.50066

Seminars in Oncology
Volume 30, Issue 2 , Pages 156-160, April 2003